Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.

It is likely that PI3K inhibitors will need to be used in combination with other drugs that induce cell stress, such as other signaling inhibitors, radio- and chemotherapy. Points at which ...

为解决乳腺癌 PI3K 抑制剂耐药问题，研究人员开展相关研究，发现耐药细胞对代谢药物敏感，或可用于临床治疗。 在全球范围内，乳腺癌是女性中最常见的癌症，也是癌症相关死亡的主要原因之一。根据激素受体（HR）和人表皮生长因子受体 2（Her2）的状态 ...

During development, cells grow, expand, and migrate to generate tissues and organs in a highly controlled manner. Many ...

Recently, the research team led by Professor Zhang Zhongtao and Professor Yao Hongwei from the General Surgery Center at ...

Itovebi, approved for some patients with breast cancer, is the first PI3K inhibitor to display a survival benefit, according ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

The company licenced its PI3 kinase inhibitors to the top biotech company Genentech for use in cancer, and in 2008, Piramed was acquired by Roche to develop the inhibitors for inflammatory diseases.

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...